New treatment to help manage pain crises in sickle cell disease at home
Official title: Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease
Funded at Ihp Therapeutics, INC. · NIH-10910229 · Data updated 2026-11-12
This study is testing a new treatment called IHP-100 to help people with sickle cell disease manage their pain at home, making it easier for them to handle painful episodes without always needing to go to the hospital.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ihp Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project start | March 5, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,192,753 |
| NIH project number | 5R44HL167473-03 |
| Project ID | NIH-10910229 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with sickle cell disease who experience acute pain crises.
✕Less likely to help
Patients who do not have sickle cell disease or those who do not experience acute pain crises may not benefit from this research.
What this research studies
This research focuses on developing a new therapeutic called IHP-100, which aims to empower patients with sickle cell disease to manage their acute pain crises at home. The treatment involves a subcutaneous injection that targets the underlying causes of vaso-occlusive crises, specifically by inhibiting P-selectin and complement activation. By addressing these key factors, the goal is to provide patients with a more effective and accessible option for pain management, reducing their reliance on healthcare facilities during painful episodes.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for patients with sickle cell disease by providing an effective at-home treatment for pain crises.
How similar studies have gone: While the approach of using glycan-based therapeutics is innovative, similar strategies targeting pain management in sickle cell disease have shown promise, indicating potential for success.
Where this research is happening
-
Ihp Therapeutics, INC.
San Carlos, United States Active
Researchers
- Principal investigator: John Paderi, John Paderi John Paderi — Ihp Therapeutics, INC.
- Study coordinator: John Paderi, John Paderi John Paderi
Related research
Other NIH-funded projects on the same topics.
-
Digital twins of the spleen to help design better therapies for sickle cell disease
A computer-driven replica of the spleen is being developed to speed up creating safer and more effective treatments for people with sickle cell disease.
-
Accelerating hydroxyurea use for sickle cell disease in Nigeria
A pragmatic study in Nigeria aims to help doctors use hydroxyurea more consistently for people with sickle cell disease.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
-
Mindfulness-based Support for Pain and Sleep in Young People with Sickle Cell Disease
A digital mindfulness program is being tailored for adolescents and young adults with sickle cell disease to help with pain and sleep and is being tested for practicality and early effectiveness.
-
How diet affects white blood cells and sickle cell disease
A study looks at how nutrition, from early life to adulthood, influences sickle cell disease by examining neutrophils and disease severity in people with SCD and in a mouse model.
-
Nutrition-based plan to ease pain in sickle cell disease
A nutrition-based approach is being tested to reduce pain for people living with sickle cell disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.